LENSAR® to Report First Quarter 2026 Results on May 8, 2026
LENSAR (Nasdaq: LNSR) will report first quarter 2026 financial results before market open on Friday, May 8, 2026.
Rhea-AI Summary
LENSAR (Nasdaq: LNSR) will report first quarter 2026 financial results before market open on Friday, May 8, 2026. Management will host a conference call and webcast at 8:30 am ET the same day to discuss results, corporate and operational highlights, and strategic initiatives.
Registration is required for telephone participation and the live webcast is available under Events & Presentations on the company investor relations website. A replay will be available through May 15, 2026.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LNSR
In the Apr 30 session, LNSR declined 2.97%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings release date
- May 8, 2026
- First quarter 2026 financial results release before market open
- Conference call time
- 8:30 am ET
- Start time for Q1 2026 earnings conference call and webcast
- Call replay end date
- May 15, 2026
- End of availability period for call and webcast replay
- Quarter reported
- First quarter 2026
- Period for upcoming financial results discussed in the announcement
Historical Context
-
Reported Q4 and full-year 2025 results with stronger recurring revenue base.
-
Alcon and LENSAR mutually ended merger after FTC opposition and review costs.
-
LENSAR detailed termination of Alcon merger and retention of $10M deposit.
-
Updated expected closing timing for Alcon acquisition amid ongoing FTC review.
-
Reported Q3 2025 results with modest revenue growth and higher SG&A expenses.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company’s first quarter 2026 financial results will be released before market open on Friday, May 8, 2026. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Friday, May 8, 2026 to discuss the results, recent corporate and operational highlights and provide an update on key strategic initiatives.
To participate by telephone, please use this registration link. All participants must use the link to complete the online registration process in advance of the conference call. The live webcast can be accessed under “Events & Presentations” in the Investor Relations section of the company’s website at https://ir.lensar.com. The call and webcast replay will be available until May 15, 2026.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.
| Contacts: | Lee Roth |
| Thomas R. Staab, II, CFO | Burns McClellan for LENSAR |
| ir.contact@lensar.com | lroth@burnsmc.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.